Venus Remedies Ltd
Venus Remedies Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue and margins.
Venus Remedies Ltd Q2 FY27 key numbers
- Revenue
- For the quarter ended 30th September 2026, consolidated revenue from operations was Rs. 219.27 crores compared to Rs. 192.75 crores for the same quarter in the previous year.
As stated in Venus Remedies Ltd's Q2 FY27 results statement · published 27 Oct 2026. Reported figures, not investment advice.
Based on Venus Remedies Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
For the quarter ended 30th September 2026, consolidated revenue from operations was Rs. EBITDA for the quarter ended 30/09/2026: Rs.
From Venus Remedies Ltd's Q2 FY27 earnings-call transcript · updated 27 Oct 2026.
Revenue & Sales Performance
- For the quarter ended 30th September 2026, consolidated revenue from operations was Rs. 219.27 crores compared to Rs. 192.75 crores for the same quarter in the previous year.
- This reflects a year-on-year revenue growth of approximately 13.75%.
- Standalone revenue from operations for the quarter was Rs. 218.76 crores as against Rs. 192.65 crores in the corresponding quarter of the previous year.
2 more points from Venus Remedies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
- EBITDA for the quarter ended 30/09/2026: Rs. 36.77 Crores
- Year-on-year (YoY) change: increased from Rs. 33.47 Crores (30/09/2025 quarter)
- Operating Margin for the quarter: Not explicitly stated as a percentage, but can be inferred from revenue and EBITDA figures:
- Revenue from Operations (30/09/2026): Rs. 329.93 Crores
- Operating margin ≈ (EBITDA / Revenue) = 36.77 / 329.93 ≈ 11.15%
- Profit after Tax (PAT) for the quarter: Rs. 25.24 Crores
2 more points from Venus Remedies Ltd's call on margins
Create a free account to keep reading this call
Venus Remedies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹219 Cr, net profit ₹26 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
Others in Pharmaceuticals & Biotechnology this season
- ERIS Lifescience (Q2 FY27)
Q2 FY27 Revenue: ₹892 crore, a 12.6% year-on-year (YoY) growth (Page 13,14) . Key investor presentation takeaways from ERIS Lifescience's Q2 FY27 investor prese
- Sat Kartar Life Ltd (Q2 FY27)
This represents a year-on-year revenue increase of approximately 26.43% [(11,387.49 . Key investor presentation takeaways from Sat Kartar Life Ltd's Q2 FY27 inv
- Sakar Healthcare Ltd (Q2 FY27)
Q2 FY27 revenue from operations: INR 8,741.61 Lakhs, up 52% YoY from INR 5,756.04 Lakhs in Q2 FY26 (Page 7). Key investor presentation takeaways from Sakar Heal
- Dr Reddys Laboratories Ltd (Q2 FY27)
Reported Q2FY27 revenues: ₹8,671 Cr, up 1.5% YoY and 7% QoQ (Page 4). Key investor presentation takeaways from Dr Reddys Laboratories Ltd's Q2 FY27 investor pre
Arthneeti Pro · Annual
Venus Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Venus Remedies Ltd Q2 FY27 results?
For the quarter ended 30th September 2026, consolidated revenue from operations was Rs. EBITDA for the quarter ended 30/09/2026: Rs.
What is Venus Remedies Ltd share price analysis?
Venus Remedies Ltd currently shows a neutral. The stock trades at a P/E of 16.8 with a market cap of ₹1,954 Cr. Investors should review the full earnings analysis for detailed insights.
Is Venus Remedies Ltd planning capital expenditure?
The provided pages of the results statement do not mention any capex, capacity expansion, new plant, or project details, including amounts, status, or timelines.
Keep Venus Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.